Xtant Medical Takes Center Stage at Canaccord Growth Conference

BELGRADE, Mont. – August 04, 2026 – In a strategic move to capture the attention of the financial community, Xtant Medical Holdings, Inc. (NYSE American: XTNT) announced today that its top leadership will present at the prestigious Canaccord Genuity 46th Annual Growth Conference in Boston next week. CEO Sean Browne, CFO Scott Neils, and COO Mark Schallenberger are scheduled to take the podium on August 11th, signaling a concerted effort to articulate the company’s growth narrative directly to institutional investors and analysts.

For a medical technology firm focused on the competitive spinal and orthopedics markets, attending such an event is more than a line on a calendar. It is a critical milestone in the journey from innovation to commercial success, a platform where strategic vision is scrutinized, financial health is stress-tested, and the pathway to profitability is laid bare. This appearance provides a crucial opportunity for Xtant to demonstrate how its portfolio of surgical solutions is translating into tangible market value.

A Strategic Play for the Investor Spotlight

The Canaccord Genuity Growth Conference is not just any industry gathering. Now in its 46th year, it has earned a reputation as a premier event for growth-focused companies, attracting nearly 2,000 attendees, including a global roster of institutional investors and financial sponsors. For the more than 400 companies presenting, it is a high-stakes arena to secure visibility and, potentially, capital.

By stepping into this spotlight, Xtant Medical is making a clear statement about its ambitions. The company aims to move beyond quarterly earnings calls and engage in a deeper dialogue about its long-term commercialization strategy. “For a company in the competitive medtech space, face-time at a conference like Canaccord is invaluable,” noted one industry analyst. “It’s their chance to tell their story directly, answer the tough questions, and build the relationships that underpin investor confidence.”

The conference's agenda, which includes other innovators in the life sciences sector like CVRx, Inc., and Pulmonx Corporation, underscores the competitive environment. Xtant’s presentation will need to cut through the noise, offering a compelling case for its unique position and future prospects. The availability of a live webcast and a 90-day replay further indicates a commitment to transparency, allowing a wider audience to assess the leadership’s message.

Navigating the Competitive Orthobiologics Landscape

Xtant Medical operates at the intersection of advanced surgical hardware and biologic materials. The company's portfolio includes spinal implant systems and a comprehensive range of orthobiologics—substances that help injuries heal—which are central to its mission of “honoring the gift of donation.” This focus places it within a dynamic and rapidly evolving market driven by an aging population, rising rates of spinal disorders, and a continuous demand for less invasive and more effective surgical outcomes.

However, the spinal solutions and orthobiologics markets are notoriously crowded and competitive. To succeed, companies must differentiate themselves through clinical efficacy, surgeon relationships, operational efficiency, and a clear commercial strategy. Xtant’s presentation at the conference will be a key opportunity to affirm its competitive advantages. Investors will be listening for updates on how the Montana-based firm is strengthening its market position, whether through new product launches, expanded distribution channels, or strategic partnerships.

This is where the journey 'from prototype to profit' becomes tangible. The management team will be expected to detail how its product development pipeline is aligned with unmet clinical needs and how its commercial team is executing on its sales strategy. Discussions during the presentation and subsequent one-on-one meetings will likely delve into market share trends, pricing power, and the company's strategy for navigating the complex reimbursement landscape—all critical factors in achieving sustained profitability.

Leadership on Display: The C-Suite Makes Its Case

The decision to send not just the CEO, but also the Chief Financial Officer and Chief Operating Officer, speaks volumes about Xtant's readiness to engage on all fronts. This trifecta of leadership allows the company to present a holistic and deeply credible picture of its operations and outlook.

CEO Sean Browne is the steward of the company’s vision, responsible for articulating its long-term strategy and positioning within the broader healthcare ecosystem. Investors will look to him for a clear narrative on where Xtant is headed and why it is poised for growth.

CFO Scott Neils provides the financial foundation for that vision. His role will be to walk investors through the numbers—revenue growth, gross margins, operating expenses, and cash flow. He will be tasked with demonstrating fiscal discipline and a clear, viable path to enhancing shareholder value.

Perhaps most critical to the 'how' of commercialization is COO Mark Schallenberger. He oversees the engine of the company: its supply chain, manufacturing, and quality control. In a field that relies on donated human tissue, operational excellence is paramount. An industry consultant commented, “Sending the CEO, CFO, and COO sends a powerful message of transparency and confidence. They're not just presenting data; they're putting their credibility on the line and are ready for scrutiny on strategy, finance, and operations.” The COO's presence assures investors that the company has the operational capacity to scale production and meet market demand reliably and efficiently.

What Investors Will Be Watching For

As Xtant's leadership prepares for Boston, the investment community will be formulating its key questions. Beyond the high-level strategy, institutional investors will be keen to understand the granular details that drive long-term success. They will be listening for updates on the integration of any recent acquisitions, progress in securing new hospital contracts, and the performance of key product lines within the orthobiologics portfolio.

The one-on-one meetings scheduled during the conference will be particularly telling. Here, away from the public presentation, sophisticated investors will conduct their due diligence, probing for details on everything from inventory management to the competitive landscape in specific geographic markets. The ability of Browne, Neils, and Schallenberger to provide confident and detailed answers will be crucial in building conviction around the stock.

Ultimately, Xtant Medical's participation in the Canaccord Genuity conference is a pivotal moment. It is an opportunity to reinforce its narrative, demonstrate its operational prowess, and convince the market that its mission-driven approach is aligned with a robust and profitable commercial future.